[
1.ALIBERTI S, BRAMBILLA AM, CHALMERS JD, CILLONIZ C, RAMIREZ J, BIGNAMINI A, PRINA E, POLVERINO E, TARSIA P, PESCI A, TORRES A, BLASI F, COSENTINI R. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respir Res. 2014 Mar 4;15(1):27.10.1186/1465-9921-15-27401514824593040
]Search in Google Scholar
[
2. SIEMIENIUK RA, BARTOSZKO JJ, ZERAATKAR D, KUM E, QASIM A, MARTINEZ JPD, IZCOVICH A, LAMONTAGNE F, HAN MA, AGARWAL A, AGORITSAS T, AZAB M, BRAVO G, CHU DK, COUBAN R, DEVJI T, ESCAMILLA Z, FOROUTAN F, GAO Y, GE L, GHADIMI M, HEELS-ANSDELL D, HONARMAND K, HOU L, IBRAHIM Q, KHAMIS A, LAM B, MANSILLA C, LOEB M, MIROSHNYCHENKO A, MARCUCCI M, MCLEOD SL, MOTAGHI S, MURTHY S, MUSTAFA RA, PARDO-HERNANDEZ H, RADA G, RIZWAN Y, SAADAT P, SWITZER C, THABANE L, TOMLINSON G, VANDVIK PO, VERNOOIJ RW, VITERI-GARCÍA A, WANG Y, YAO L, ZHAO Y, GUYATT GH, BRIGNARDELLO-PETERSEN R. Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980.10.1136/bmj.m2980739091232732190
]Search in Google Scholar
[
3. ASSIMAKOPOULOS SF, MARANGOS M. N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome. Med Hypotheses. 2020;140:109778.10.1016/j.mehy.2020.109778719502832344315
]Search in Google Scholar
[
4. du PREEZ HN, ALDOUS C, KRUGER HG, JOHNSON L. N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19. Adv Pharmacol Pharm Sci. 2022;2022:4555490.10.1155/2022/4555490938528535992575
]Search in Google Scholar
[
5. WAN X, WANG W, LIU J, TONG T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.10.1186/1471-2288-14-135438320225524443
]Search in Google Scholar
[
6. AVDEEV SN, GAYNITDINOVA VV, MERZHOEVA ZM, BERIKKHANOV ZG. N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. J Infect. 2022;84(1):94–118.10.1016/j.jinf.2021.07.003827103134252497
]Search in Google Scholar
[
7. GAYNITDINOVA V.V., AVDEEV S.N., MERZHOEVA Z.M., BERIKKHANOV Z.G., MEDVEDEVA I.V., GORBACHEVA T.L. N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia. PULMONOLOGIYA. 2021;31(1):21–29.10.18093/0869-0189-2021-31-1-21-29
]Search in Google Scholar
[
8. MOUSAPOUR P, HAMIDI FARAHANI R, MOSAED R, ASGARI A, HAZRATI E. Efficacy and safety of acetylcysteine for the prevention of liver injury in COVID-19 intensive care unit patients under treatment with remdesivir. Gastroenterol Hepatol Bed Bench. 2022;15(3):241–248.
]Search in Google Scholar
[
9. TAHER A, LASHGARI M, SEDIGHI L, RAHIMI-BASHAR F, POOROLAJAL J, MEHRPOOYA M. A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. Pharmacol Rep. 2021;73(6):1650–165910.1007/s43440-021-00296-2819171234114174
]Search in Google Scholar
[
10. de ALENCAR JCG, MOREIRA CL, MÜLLER AD, et al. Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2021;72(11):e736–e741.
]Search in Google Scholar
[
11. IZQUIERDO JL, SORIANO JB, GONZÁLEZ Y, et al. Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. Sci Prog. 2022;105(1):368504221074574.10.1177/00368504221074574879575535084258
]Search in Google Scholar
[
12. ASSIMAKOPOULOS SF, ARETHA D, KOMNINOS D, et al. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. Infect Dis (Lond). 2021;53(11):847–854.10.1080/23744235.2021.194567534182881
]Search in Google Scholar
[
13. FAVERIO P, REBORA P, ROSSI E, et al. Impact of N-acetyl-l-cysteine on SARS-CoV-2
]Search in Google Scholar
[
14. KHOONSARI M, ZAMANI F, KARBALAIE NIYA M H, HEMMASI G, AJDARKOSH H, et al. Liver Enzymes and Inpatient Deaths in COVID-19 Hospitalized Patients. Hepat Mon. 2020;20(11):e109076.10.5812/hepatmon.109076
]Search in Google Scholar
[
15. CARRILLO HERNANDEZ-RUBIO J, SANCHEZ-CARPINTERO ABAD M, YORDI LEON A, et al. Outcomes of an intermediate respiratory care unit in the COVID-19 pandemic. PLoS One. 2020;15(12):e0243968.10.1371/journal.pone.0243968774398533326484
]Search in Google Scholar
[
16. TSERMPINI EE, GLAMOČLIJA U, ULUCAN-KARNAK F, REDENŠEK TRAMPUŽ S, DOLŽAN V. Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review. Antioxidants (Basel). 2022;11(8):1609.10.3390/antiox11081609940544436009328
]Search in Google Scholar
[
17. du PREEZ HN, ALDOUS C, KRUGER HG, JOHNSON L. N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19. Adv Pharmacol Pharm Sci. 2022;2022:4555490.10.1155/2022/4555490938528535992575
]Search in Google Scholar
[
18. JIANG C, ZOU J, LV Q, YANG Y. Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Palliat Med. 2021;10(6):6564–6576.10.21037/apm-21-113834237968
]Search in Google Scholar
[
19. POOLE P, SATHANANTHAN K, FORTESCUE R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;5(5):CD001287.10.1002/14651858.CD001287.pub6652742631107966
]Search in Google Scholar
